Protagenic Therapeutics Warrant
PTIXW
PTIXW was delisted on the 2nd of January, 2026.
3 hedge funds and large institutions have $2.76K invested in Protagenic Therapeutics Warrant in 2024 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 1 increasing their positions, 0 reducing their positions, and 1 closing their positions.
47% more capital invested
Capital invested by funds: $1.87K → $2.76K (+$883)
0.41% more ownership
Funds ownership: 5.16% → 5.57% (+0.41%)
25% less funds holding
Funds holding: 4 → 3 (-1)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$228 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of America
Charlotte,
North Carolina
|
-$1 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
WAM
1
Warberg Asset Management
Winnetka,
Illinois
| $2.11K | – | – | – |
|
|
2
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $420 | +$228 | +20,015 | +75% |
|
|
GS
3
GTS Securities
New York
| $228 | – | – | – |
|
|
4
Bank of America
Charlotte,
North Carolina
| – | -$1 | -100 | Closed |
|
PTIXW Hedge Fund Activity: Q3 2024 in Review
3 of the 6,965 institutional investors tracked by Wall St. Rank reported a position in Protagenic Therapeutics Warrant (PTIXW) for Q3 2024, worth a combined $2.76K — up 47% from $1.87K a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of PTIXW and 0 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 1 added.
The largest buyer was Susquehanna International Group, adding an estimated $228. The largest seller was Bank of America, exiting entirely with an estimated $1 sold.
- 3 institutional investors held Protagenic Therapeutics Warrant (PTIXW) as of Q3 2024, down from 4 in Q2 2024.
- Funds reported $2.76K of Protagenic Therapeutics Warrant stock for Q3 2024, up 47% quarter-over-quarter.
- 0 funds opened new Protagenic Therapeutics Warrant positions in Q3 2024 and 1 closed out, a net change of -1 holder.
- The largest Protagenic Therapeutics Warrant buyer in Q3 2024 was Susquehanna International Group, an estimated $228 added.
- The largest Protagenic Therapeutics Warrant seller in Q3 2024 was Bank of America, an estimated $1 sold.
Based on aggregated 13F filings for Q3 2024.